Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Human Vaccines & Immunotherapeutics

• Publication date

  2013-07-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.4161/hv.25562PMID 23839107PMCID PMC3981840
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years

  2012cited by this paper
• Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

  2012cited by this paper
• Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

  2011cited by this paper
• Epidemiological characteristics of the 2005 and 2007 dengue epidemics in Singapore - similarities and distinctions.

  2011cited by this paper
• From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

  2011cited by this paper
• Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.

  2011cited by this paper
• Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.

  2011cited by this paper
• Update on Dengue: Epidemiology, Virus Evolution, Antiviral Drugs, and Vaccine Development

  2010cited by this paper
• Critical parameters in blood processing for T-cell assays: validation on ELISpot and tetramer platforms.

  2010cited by this paper
• Dengue: a continuing global threat

  2010cited by this paper
• A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.

  2010cited by this paper
• Dengue vaccine candidates in development.

  2010cited by this paper
• Delayed processing of blood increases the frequency of activated CD11b+ CD15+ granulocytes which inhibit T cell function.

  2009cited by this paper
• Towards a dengue vaccine: progress to date and remaining challenges.

  2008cited by this paper
• Understanding the contribution of cellular immunity to dengue disease pathogenesis

  2008cited by this paper
• Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.

  2008cited by this paper
• Prospects for a dengue virus vaccine

  2007cited by this paper
• Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok

  2006cited by this paper
• Immunopathological mechanisms in dengue and dengue hemorrhagic fever

  2006cited by this paper
• Development of a Live Attenuated Dengue Virus Vaccine Using Reverse Genetics

  2006cited by this paper
• Altered Cytokine Responses of Dengue-Specific CD4+ T Cells to Heterologous Serotypes 1

  2005cited by this paper
• Intracellular T-cell cytokine levels are age-dependent in healthy children and adults.

  2005cited by this paper
• Dengue: defining protective versus pathologic immunity.

  2004cited by this paper
• Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren.

  2002cited by this paper
• Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine

  2001cited by this paper
• IL-13 and IFN-gamma secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression.

  1999cited by this paper
• Interleukin-4 and interleukin-13: their similarities and discrepancies.

  1998cited by this paper
• The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes.

  1997cited by this paper
• Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells.

  1994cited by this paper

• State of the Art on Vaccine Development Against Dengue Infection: Scoping Review of the Literature

  2025cites this paper
• Long term T cell response and safety of a tetravalent dengue vaccine in healthy children

  2024cites this paper
• A semi high-throughput whole blood-based flow cytometry assay to detect and monitor Bordetella pertussis-specific Th1, Th2 and Th17 responses

  2023cites this paper
• Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia.

  2022cites this paper
• Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.

  2022cites this paper
• Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model

  2022cites this paper
• Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults

  2022cites this paper
• Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021

  2021cites this paper
• Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

  2021cites this paper
• Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?

  2020cites this paper
• Uncovering Distinct Primary Vaccination-Dependent Profiles in Human Bordetella pertussis Specific CD4+ T-Cell Responses Using a Novel Whole Blood Assay

  2020cites this paper
• Dengue hemorrhagic fever - A systemic literature review of current perspectives on pathogenesis, prevention and control.

  2020cites this paper
• A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice

  2020cites this paper
• When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?

  2020cites this paper
• CD8+ T cells mediate protection against Zika virus induced by an NS3-based vaccine

  2020cites this paper
• Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.

  2020cites this paper
• Anti-dengue Vaccines: From Development to Clinical Trials

  2020cites this paper
• Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?

  2019cites this paper
• A review of Dengvaxia®: development to deployment

  2019cites this paper
• Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?

  2019cites this paper
• Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.

  2019cites this paper
• Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development

  2019cites this paper
• A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies

  2019cites this paper
• Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials

  2019influential citation
• Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis

  2019cites this paper
• Regulation and Function of NK and T Cells During Dengue Virus Infection and Vaccination

  2018influential citation
• Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine.

  2018cites this paper
• Memory T Cells in Flavivirus Vaccination

  2018influential citation
• Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America

  2018cites this paper
• A recombinant live attenuated tetravalent vaccine for the prevention of dengue

  2017cites this paper
• Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development

  2017cites this paper
• Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding

  2017influential citation
• T Cell Immunity and Zika Virus Vaccine Development.

  2017cites this paper
• CD4+ and CD8+ T‐cell immunity to Dengue – lessons for the study of Zika virus

  2017cites this paper
• Bruno Guy Vaccines : Example of the Sanofi Pasteur Tetravalent Dengue Vaccine Questions Raised by the Development and Implementation of Dengue We Be Concerned about Enhanced Disease after Vaccination ? : Which Dengue Vaccine Approach

  2017cites this paper
• Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?

  2016cites this paper
• T cell immunity to dengue virus and implications for vaccine design

  2016cites this paper
• Vaccination Against Dengue: Challenges and Current Developments.

  2016cites this paper
• Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease

  2016cites this paper
• Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

  2016cites this paper
• Analysis of cell-mediated immune responses in support of dengue vaccine development efforts.

  2015cites this paper
• Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.

  2015cites this paper
• Dengue virus envelope protein domain I/II hinge: a key target for dengue virus vaccine design?

  2015cites this paper
• Dengue vaccine: hypotheses to understand CYD-TDV-induced protection

  2015cites this paper
• The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response

  2015cites this paper
• Molecular mechanisms of dengue virus infection: cell tropism, antibody-dependent enhancement, and cytokines

  2015cites this paper
• Immunopathogenesis versus Protection in Dengue Virus Infections

  2014cites this paper
• Dengue Vaccine Development: An Update

  2014cites this paper
• Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patients.

  2014cites this paper
• Recent progress in dengue vaccine development

  2014cites this paper
• Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections.

  2014cites this paper
• Identification of Conserved and HLA Promiscuous DENV3 T-Cell Epitopes

  2013cites this paper
• | Efficacy Levels of Recombinant Tetravalent Dengue Vaccine (Cyd-Tdv) in Children Aged 2-16 Years

  year unknowncites this paper